Table 1.
Patients Characteristics among Our Cohort Prior and after Match (Good vs Poor PS)
| Patients characteristics (n=114) | Frequency (%), Median (IQR) | ||
|---|---|---|---|
| Good PS (n=82) | Poor PS (n=32) | P value | |
| Age; yrs | 45 (22-68) | 48 (40.3-57.8) | 0.13 |
| Male gender | 43 (52.4) | 23 (71.9) | 0.059 |
| Weight; Kg | 77 (65-88) | 88.5 (78.3-95.5) | 0.001 |
| Chronic disease | 23 (28) | 10 (31.3) | 0.735 |
| Asbestos | 65 (79.3) | 21 (65.6) | 0.128 |
| Smokers | 30 (36.6) | 12 (37.5) | 0.928 |
| Dyspnea | 76 (92.7) | 29 (90.6) | 0.714 |
| Chest pain | 72 (87.8) | 26 (81.3) | 0.365 |
| Grade 2 Chest pain | 35 (45.5) | 0 (0) | 0.001 |
| Cough | 44 (53.7) | 20 (62.5) | 0.393 |
| Fatigue | 53 (64.6) | 23 (71.9) | 0.461 |
| Anorexia | 19 (23.2) | 16 (50) | 0.005 |
| Pleural effusion | 69 (84.1) | 31 (96.9) | 0.063 |
| Pleural thickening | 78 (95.1) | 31 (96.9) | 0.881 |
| T4 stage | 14 (17.1) | 5 (15.6) | 0.852 |
| N+ | 27 (32.9) | 8 (25) | 0.41 |
| M+ | 10 (12.2) | 5 (15.6) | 0.626 |
| IMIG stage III/IV | 59 (72) | 20 (62.5) | 0.326 |
| Pretreatment hemoglobin; g/dL | 12 (10.8-12.9) | 11.15 (10-12) | 0.043 |
| Platelets; / μL | 372,000 (306,000-473,500) | 316,000 (214,000-464,000) | 0.054 |
| WBC; /μL | 9,660 (7,498-12,000) | 10.6 (925,000-12,000) | 0.113 |
| Neutrophils; /μL | 6,100 (4,400-7,250) | 6,200 (4,550-7,275) | 0.762 |
| Lymphocytes; /μL | 1,850 (1,000-2,400) | 1,000 (800-1,800) | 0.001 |
| NLR | 3.6 (4.31-2.76) | 5.3 (3.97-8.77) | 0.001 |
| Epithelial histology | 49 (59.8) | 18 (56.3) | 0.566 |
| Median OS(months;IQR) | 17 (14-19.9) | 16 (12.7-19.3) | 0.383 |
| Median PFS | 9 (7-11) | 8 (6.6-9.6) | 0.121 |
| Median TTP | 10 (8.2-11.8) | 8 (5.8-10.2) | 0.258 |
| Median Follow up | 16 | 16.5 | … |
| After Propensity score Match(n=58) | |||
| Good PS (n=29) | Poor PS (n=29) | P value | |
| Age;(> Median 45 yrs) | 13 (44.8%) | 14 (48.3%) | 0.792 |
| Male gender | 18 (62.1%) | 20 (69%) | 0.581 |
| Weight(> median 77kg) | 16 (55.2%) | 21 (72.4%) | 0.172 |
| Chronic disease | 10 (34.5%) | 9 (31%) | 0.78 |
| Asbestos | 25 (86.2%) | 20 (69%) | 0.115 |
| Smokers | 10 (34.5%) | 11 (37.9%) | 0.785 |
| IMIG stage IV | 7 (24.1%) | 9 (31%) | 0.52 |
| Pretreatment hemoglobin; g/dL | 11.9 (10.6-12.9) | 11 (10-12) | 0.123 |
| Platelets; /μL | 369,000 (328,000-482,000) | 321,000 (214,000-549,000) | 0.146 |
| WBC; /μL | 11,000 (9,000-12,150) | 10.2 (8,900-12,000) | 0.732 |
| Neutrophils; /μL | 6,600 (3,800-7,750) | 6,100 (4,450-6,850) | 0.544 |
| Lymphocytes; /μL | 1,800 (1,000-2,300) | 1,000 (800-1,800) | 0.013 |
| NLR | 3.92 (2.60-6.20) | 5.30 (3.74-9.23) | 0.027 |
| Epithelial histology | 19 (65.5%) | 16 (55.2%) | 0.421 |
LN, lymph node; N, nodal stage; M, metastasis stage; IMIG, International mesothelioma Interest Group staging; WBCs, white blood cells; OS, overall survival; IQR, inter-quartile range; PFS, progression free survival; TTP, time to progression